Minter-Dykhouse Katherine, Nelson Timothy J, Folmes Clifford D L
Stem Cell and Regenerative Metabolism Laboratory, Departments of Cardiovascular Diseases, Biochemistry and Molecular Biology, and Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona, USA.
Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome, Departments of General Internal Medicine and Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Stem Cells Dev. 2022 Sep;31(17-18):521-528. doi: 10.1089/scd.2022.0041. Epub 2022 Jul 25.
Lineage-specific differentiation of human-induced pluripotent stem cells (hiPSCs) into cardiomyocytes (CMs) offers a patient-specific model to dissect development and disease pathogenesis in a dish. However, challenges exist with this model system, such as the relative immaturity of iPSC-derived CMs, which evoke the question of whether this model faithfully recapitulates in vivo cardiac development. As in vivo cardiac developmental stage is intimately linked with the proliferative capacity (or maturation is inversely correlated to proliferative capacity), we sought to understand how proliferation is regulated during hiPSC CM differentiation and how it compares with in vivo mouse cardiac development. Using standard Chemically Defined Media 3 differentiation, gene expression profiles demonstrate that hiPSC-derived cardiomyocytes (hiPSC-CMs) do not progress past the equivalent of embryonic day 14.5 of murine cardiac development. Throughout differentiation, overall DNA synthesis rapidly declines with <5% of hiPSC-CMs actively synthesizing DNA at the end of the differentiation period despite their immaturity. Bivariate cell cycle analysis demonstrated that hiPSC-CMs have a cell cycle profile distinct from their non-cardiac counterparts from the same differentiation, with significantly fewer cells within G1 and a marked accumulation of cells in G2/M than their non-cardiac counterparts throughout differentiation. Pulse-chase analysis demonstrated that non-cardiac cells progressed completely through the cell cycle within a 24-h period, whereas hiPSC-CMs had restricted progression with only a small proportion of cells undergoing cytokinesis with the remainder stalling in late S-phase or G2/M. This cell cycle arrest phenotype is associated with abbreviated expression of cell cycle promoting genes compared with expression throughout murine embryonic cardiac development. In summary, directed differentiation of hiPSCs into CMs uncouples the developmental stage from cell cycle regulation compared with in vivo mouse cardiac development, leading to a premature exit of hiPSC-CMs from the cell cycle despite their relative immaturity.
将人诱导多能干细胞(hiPSC)定向分化为心肌细胞(CM),为在培养皿中剖析发育过程和疾病发病机制提供了一个患者特异性模型。然而,该模型系统存在一些挑战,例如iPSC衍生的CM相对不成熟,这引发了该模型是否能如实再现体内心脏发育的问题。由于体内心脏发育阶段与增殖能力密切相关(或者说成熟度与增殖能力呈负相关),我们试图了解hiPSC向CM分化过程中增殖是如何调控的,以及它与体内小鼠心脏发育相比情况如何。使用标准的化学成分确定培养基3进行分化,基因表达谱表明,hiPSC衍生的心肌细胞(hiPSC-CM)在发育阶段上没有超过小鼠心脏发育的胚胎第14.5天。在整个分化过程中,总体DNA合成迅速下降,尽管hiPSC-CM不成熟,但在分化期末只有不到5%的hiPSC-CM积极合成DNA。双变量细胞周期分析表明,hiPSC-CM具有与同一分化过程中的非心肌对应细胞不同的细胞周期谱,在整个分化过程中,处于G1期的细胞明显少于非心肌对应细胞,而处于G2/M期的细胞则显著积累。脉冲追踪分析表明,非心肌细胞在24小时内完全经历细胞周期,而hiPSC-CM的进展受限,只有一小部分细胞进行胞质分裂,其余细胞停滞在S期晚期或G2/M期。与小鼠胚胎心脏发育全程的表达相比,这种细胞周期停滞表型与细胞周期促进基因的表达缩短有关。总之,与体内小鼠心脏发育相比,hiPSC向CM的定向分化使发育阶段与细胞周期调控脱钩,导致hiPSC-CM尽管相对不成熟但仍过早退出细胞周期。